An epidemic of metabolic diseases including type 2 diabetes and obesity is undermining the health of people living in industrialized societies. There is an urgent need to develop innovative therapeutics.
University of California, Irvine scientists have developed potent, novel small molecule modulators against a new target. Evaluation of these modulators with a mouse model of hyperglycemia showed a dose-dependent effect in glucose clearance. Circulating glucose was also reduced in diet-induced and genetic diabetes (db/db) mouse models. These novel small molecule modulators may prove useful for the treatment or prevention of diabetes and metabolic disorders.
University of California, Irvine scientists continue to evaluate the efficacy of these novel compounds. A patent application was filed and the university is seeking a licensee to further develop this exciting technology.
Country | Type | Number | Dated | Case |
United States Of America | Issued Patent | 8,722,896 | 05/13/2014 | 2009-321 |